Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2006 1
2011 1
2012 1
2013 1
2014 2
2015 4
2016 10
2017 6
2018 4
2019 3
2020 9
2021 8
2022 6
2023 6
2024 6
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Results by year

Filters applied: . Clear all
Page 1
Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy in patients with advanced HER2-negative gastric or gastro-oesophageal junction cancer (ARMANI): a randomised, open-label, multicentre, phase 3 trial.
Randon G, Lonardi S, Fassan M, Palermo F, Tamberi S, Giommoni E, Ceccon C, Di Donato S, Fornaro L, Brunetti O, De Vita F, Bittoni A, Chini C, Spallanzani A, Nappo F, Bethaz V, Strippoli A, Latiano T, Cardellino GG, Giuliani F, Morano F, Niger M, Raimondi A, Prisciandaro M, Pircher CC, Sciortino C, Marchesi S, Garattini SK, Airò G, Miceli R, Di Bartolomeo M, Pietrantonio F. Randon G, et al. Among authors: strippoli a. Lancet Oncol. 2024 Dec;25(12):1539-1550. doi: 10.1016/S1470-2045(24)00580-1. Epub 2024 Nov 15. Lancet Oncol. 2024. PMID: 39557058 Clinical Trial.
Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONO.
Raimondi A, Lonardi S, Murgioni S, Cardellino GG, Tamberi S, Strippoli A, Palermo F, De Manzoni G, Bencivenga M, Bittoni A, Chiodoni C, Lorenzini D, Todoerti K, Manca P, Sangaletti S, Prisciandaro M, Randon G, Nichetti F, Bergamo F, Brich S, Belfiore A, Bertolotti A, Stetco D, Guidi A, Torelli T, Vingiani A, Joshi RP, Khoshdeli M, Beaubier N, Stumpe MC, Nappo F, Leone AG, Pircher CC, Leoncini G, Sabella G, Airo' Farulla L, Alessi A, Morano F, Martinetti A, Niger M, Fassan M, Di Maio M, Kaneva K, Milione M, Nimeiri H, Sposito C, Agnelli L, Mazzaferro V, Di Bartolomeo M, Pietrantonio F. Raimondi A, et al. Among authors: strippoli a. Ann Oncol. 2025 Mar;36(3):285-296. doi: 10.1016/j.annonc.2024.11.016. Epub 2024 Dec 3. Ann Oncol. 2025. PMID: 39637944 Free article. Clinical Trial.
Gastric Cancer, Immunotherapy, and Nutrition: The Role of Microbiota.
Raoul P, De Gaetano V, Sciaraffia G, Ormea G, Cintoni M, Pozzo C, Strippoli A, Gasbarrini A, Mele MC, Rinninella E. Raoul P, et al. Among authors: strippoli a. Pathogens. 2024 Apr 26;13(5):357. doi: 10.3390/pathogens13050357. Pathogens. 2024. PMID: 38787209 Free PMC article. Review.
Adjuvant TRastuzumab deruxtecan plus fluoropyrimidine versus standard chemotherapy in HER2-positive gastric or gastroesophageal cancer patients with persistence of minimal residual disease in liquid biopsy after pre-operative chemotherapy and radical surgery: the multicentre, phase II randomized TRINITY trial.
Nasca V, Bergamo F, Foltran L, Antonuzzo L, Bencardino K, Dell'Aquila E, Corallo S, Spallanzani A, Brunetti O, Spada D, Tamberi S, Cella CA, Avallone A, Fornaro L, Di Donato S, Strippoli A, Puccini A, Tamburini E, Palermo F, Morano F, Pietrantonio F, Raimondi A. Nasca V, et al. Among authors: strippoli a. BMC Cancer. 2025 Apr 8;25(1):633. doi: 10.1186/s12885-025-14063-6. BMC Cancer. 2025. PMID: 40200187 Free PMC article.
Impact of age and sex on the efficacy and safety of ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line oxaliplatin-based chemotherapy: a subgroup analysis of the ARMANI phase III trial.
Fazio R, Randon G, Bergamo F, Palermo F, Tamberi S, Giommoni E, Di Donato S, Fornaro L, Brunetti O, De Vita F, Valgiusti M, Gobba SM, Spallanzani A, Murgioni S, Bethaz V, Strippoli A, Latiano TP, Cardellino GG, Ceccon C, Raimondi A, Prisciandaro M, Pircher CC, Ambrosini M, Manca P, Fassan M, Di Bartolomeo M, Di Maio M, Pietrantonio F. Fazio R, et al. Among authors: strippoli a. ESMO Open. 2025 Jul;10(7):105329. doi: 10.1016/j.esmoop.2025.105329. Epub 2025 Jun 19. ESMO Open. 2025. PMID: 40540760 Free PMC article. Clinical Trial.
Prognostic value of skeletal muscle mass during tyrosine kinase inhibitor (TKI) therapy in cancer patients: a systematic review and meta-analysis.
Rinninella E, Cintoni M, Raoul P, Ponziani FR, Pompili M, Pozzo C, Strippoli A, Bria E, Tortora G, Gasbarrini A, Mele MC. Rinninella E, et al. Among authors: strippoli a. Intern Emerg Med. 2021 Aug;16(5):1341-1356. doi: 10.1007/s11739-020-02589-5. Epub 2020 Dec 18. Intern Emerg Med. 2021. PMID: 33337518 Free PMC article.
68 results